A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

NCT06902545 · clinicaltrials.gov ↗

RECRUITING

Status

377

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Metastatic Gastric Adenocarcinoma or Cancer
Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions

DRUG: zolbetuximab

Sponsor

Astellas Pharma Korea, Inc.